Synovial Sarcoma Exhibits Emerging Pipeline with 22 Drug Candidates

Synovial Sarcoma Therapeutics Pipeline

The study analysed that the Synovial sarcoma pipeline comprises of 22 drug candidates in different stages of development. Synovial sarcoma is rare type of cancer and approximately one to three people in one million people are diagnosed with synovial sarcoma every year, globally. The disease occurs frequently in young adults; however, the disease can affect a person at any age. Synovial sarcoma is more common in males, and the male to female ratio of the disease stands at 12 males for every 10 females. Various new therapies and advanced technologies are driving the growth of Synovial sarcoma pipeline.

Many technologies such as REOLYSIN technology, ZVex and GLAAS technology, Laser Micro-beam Microdissection are being developed that can bring the innovative treatment, which can control the progression of Synovial sarcoma.  ZVex and GLAAS are complementary discovery platforms designed to activate and expand the immune system’s natural ability to create tumour-specific cytotoxic T cells (CTLs) in vivo.

The combination of novel drugs against different organs as well as combination of drugs with biological and biochemical agents may further enhance the treatment quality.

The research also found that various companies have collaborated for the development of Synovial sarcoma pipeline. In February 2014, Pfizer Inc. (Pfizer) and Merck & Co., Inc. (Merck) agreed to explore the therapeutic potential of Merck’s investigational anti-PD-1 therapy, MK-3475, in combination with two of the Pfizer’s oncology assets.

Some of the key players developing drugs for Synovial sarcoma include Takara Bio Inc., Oncolytics Biotech Inc., Accuronix Therapeutics, Inc., Cue Biopharma, Inc. and others.

News Courtesy: P&S Market Research

Advertisements

Post-Traumatic Stress Disorder Exhibits Emerging Pipeline with 23 Drug Candidates

Post-Traumatic Stress DisorderThe study analysed that the PTSD pipeline comprises of 23 drug candidates in different stages of development. PTSD is a neurological disorder that develops in people who have experienced a scary or a dangerous event. PTSD can occur in a person at any age. According to the National Center of PTSD, around seven to eight out of 100 individuals experience PTSD at some point in their lives. Most of the people recover from traumatic situation naturally, but those who continue to experience problems are diagnosed with PTSD. People with PTSD are used to feel frightened even when they are not in a dangerous situation. PTSD generally occurs more often in women than men. Various collaboration between educational institutes, associations, and pharma companies are driving the therapeutic pipeline of PTSD.

Many patents have been received during the development of drug candidates for the treatment of PTSD. In May 2017, Tonix reported the issuance of patent 9 636 408 by the United States Patent and Trademark Office titled “Eutectic Formulations of Cyclobenzaprine Hydrochloride and Amitriptyline Hydrochloride,” covering the composition and manufacture of its proprietary sublingual formulation of very low dose cyclobenzaprine.

Significant growth in the therapeutic pipeline of PTSD is attributed to increasing collaboration between educational institutes, associations and pharma companies. Funds from the non-profit organizations have also been supporting the pipeline growth of PTSD therapeutics.

Some of the key players developing drugs for the treatment of PTSD include India Globalization Capital, Inc., Therapade Technologies LLC, Axim Biotechnologies, Inc. and others.

News Courtesy: P&S Market Research

Diabetic Foot Ulcer Therapeutics Pipeline Analysis, 2017

The study analysed that the diabetic foot ulcer pipeline comprises of approximately 27 drug candidates in different stages of development.

Diabetic foot ulcer is a serious complication of diabetes and can be defined as the ulceration in foot along with neuropathy or peripheral artery disease of the lower limb in diabetic patients. Diabetic foot ulcer is categorized into two types namely; neuropathic foot where neuropathy dominates and neuroischemic foot where occlusive vascular disease is the main factor. Diabetic neuropathy, peripheral artery disease and consequent trauma of the foot are the major risk factors for diabetic foot ulcer. The motor and sensory nerve damage can caus muscle weakness, paresis and atrophy in diabetic patients. Diabetic foot ulcer can be assessed by physical examination of the skin for the vascular, neurological, and musculoskeletal systems. Additionally, this examination also involves the assessment of perception of superficial pain, and temperature. Neuropathic disability score is assessed to evaluate the risk of occurrence of neuropathic ulceration.

Most of the innovations in technology have been producing novel therapies for the treatment of diabetic foot ulcer. NOx is an advanced wound care technology invented by Edixomed Ltd, that provides the important moist environment, which aids in healing and absorbs wound exudate that generates nitric oxide.

Some of the key players developing drugs for the treatment of diabetic foot ulcer include Lakewood Amedex, Inc., Edixomed Ltd., CardioVascular BioTherapeutics Inc. and others.

News Courtesy: P&S Market Research

Expanded License Indications for Fibrin Glues is the Major Trend being Observed in the Global Fibrin Glue Market

 

Fibrin Glue MarketAccording to the study, the global fibrin glue market is likely to grow significantly during the forecast period, mainly due to increasing number of surgical procedures and burn cases, and rising healthcare expenditure. According to the data provided by the World Bank, 30,537 surgeries were performed per 100,000 population, in 2012, in the U.S. Similarly, in 2015, number of surgical procedures performed in Australia were 28,907 per 100,000 population. Fibrin glue is used in various types of surgeries. Fibrin glue is also used in burn cases during plastic surgeries and surgery of the burned body parts. According to WHO, approximately 265,000 deaths every year are caused by burns. Additionally, increasing prevalence of chronic diseases and low chances of complications associated with these products and rise in the number of road accidents also contributes to the growth of the overall market. However, increasing minimally invasive procedures and stringent regulatory requirements are some of the key factors restraining the growth of global fibrin glue market.

Geographically, North America has been the largest market for fibrin glue, with the U.S. being the larger contributor to the regional market, compared to Canada. High prevalence of cardiovascular diseases is a key factor driving the growth of North America fibrin glue market for cardiac surgery. Additionally, the growth of the fibrin glue market in this region is driven by the rise in number of surgical procedures; especially plastic surgeries in the region, high expenditure on healthcare, increasing geriatric population, high number of road accidents and burn cases. According to American Heart Association (AHA), around 85.6 million people are living with cardiovascular diseases, in the U.S. According to Centers for Disease Control and Prevention (CDC), total national healthcare expenditure in the U.S. was $3.0 trillion in 2014 and per capita national health expenditure was $9,523. According to the American Society of Plastic Surgeons, around 14.6 million cosmetic plastic surgeries were carried out in the U.S. in 2012, which was 5% higher as compared to 2011. According to a United Nations publication, the population of people aged 60 years and above in North America was approximately 74.6 million in 2015, and the number is estimated to reach approximately 104.8 million by 2030. Thus, the demand for fibrin glue products is expected to increase in the region.

Some of the key players operating in the global fibrin glue market include Vivostat A/S, Kaketsuken, Johnson & Johnson, Baxter International Inc., CSL Behring, Zimmer Biomet Holdings, Inc., Takeda Pharmaceutical Company Limited, Mallinckrodt Plc, Shanghai RAAS Blood Products Co. Ltd. and Hualan Biological Engineering Inc.

News Courtesy: P&S Market Research

Digital Health Market is Driven by Growing Demand for Advanced Healthcare Information System

Global Digital Health Market

The global digital health market is growing at a significant rate, due to growing demand for advanced healthcare information system, and growing investment by healthcare information technology (HIT) players. The growing need for remote patient monitoring services, increasing support from government organizations and growing demand for mHealth technologies are also driving the growth of the global digital health market. However, the factors such as privacy and security issues, inadequate healthcare infrastructure in developing economies, and high capital expenditure and maintenance requirement are inhibiting the growth of the global market.

Digital health technologies, such as electronic health records (EHR), digital diagnostic systems, and wireless technologies comprises a range of data including patient history, immunization dates, medication, allergies, diagnosis, radiology images, laboratory and test results, insurance information, and treatment plans. Moreover, the digital health technologies help to improve communication between patients and healthcare providers to reduce medical errors for better coordinated care. These technologies also help to share information with other healthcare organizations and providers, such as medical imaging facilities, emergency facilities, laboratories, clinics, and pharmacies.

Some of the key companies operating in the global digital health market include AT&T Inc., Cerner Corporation, Cisco Systems Inc., General Electric Company, McKesson Corporation, Koninklijke Philips N.V., Qualcomm Incorporated, eClinicalWorks, Allscripts Healthcare Solutions Inc., athenahealth Inc., and Epic Systems Corporation.

News Courtesy: P&S Market Research

ER+ Breast Cancer Exhibits Emerging Pipeline with 45+ Drug Candidates

ER+ Breast Cancer

The study analyzed that the estrogen receptor positive breast cancer pipeline comprises approximately 74 drug candidates in different stages of development.

As per the findings of the research, a major share of ER+ breast cancer pipeline drug candidates are being developed to be administered by oral route.

Chipscreen Biosciences, Ltd. is using chemo genomics approach for the development of their drug candidates in ER+ breast cancer. The approach connects small molecule structures to disease targets and therapeutic functions to accelerate the discovery process by effectively comparing the molecular profiles of successful drugs, failed drugs, and classical toxins.

The research finds that different companies have collaborated for the development of ER+ breast cancer. In January 2016, Radius Health, Inc. entered in a worldwide clinical collaboration with Novartis Pharmaceuticals to evaluate the safety and efficacy of combining investigational agent RAD1901 with LEE011 for advanced breast cancer.

Some of the key players developing drugs for Estrogen Receptor-Positive (ER+) breast cancer are Chipscreen Biosciences, Ltd., Eli Lilly & Company, Genentech, Inc., and others.

News Courtesy: P&S Market Research

Alzheimer’s Disease Exhibits Emerging Pipeline with 80+ Drug Candidates

Alzheimer_s Disease Pipeline Analysis

The study analyzed that the Alzheimer’s disease pipeline comprises 89 drug candidates in different stages of development.

As per the findings of the research, majority of the active drug candidates of Alzheimer’s disease pipeline are being developed to be administered by oral route.

AC Immune, Ltd. is using SupraAntigen technology platform for the development of Crenezumab, ACI-24 and ACI-35 for Alzheimer’s disease. This technology is used to produce conformation specific antibodies and is used to create products for active immunization (vaccines) and passive immunization (antibodies).

The research finds that different companies have collaborated for the development of Alzheimer’s disease pipeline. In March 2014, Eisai Co., Ltd. and Biogen Idec collaborated to develop and commercialize two of Eisai’s clinical candidates, E2609 and BAN2401, for Alzheimer’s disease.

Some of the key players developing drugs for Alzheimer’s disease are Eli Lilly and Company, Genentech, Inc., Eisai Co., Ltd., and others.

News Courtesy: P&S Market Research

Amyotrophic Lateral Sclerosis Exhibits Emerging Pipeline with 50+ Drug Candidates

Amyotrophic Lateral Sclerosis

The study analysed that the Amyotrophic lateral sclerosis pipeline comprises of 72 drug candidates in different stages of development.

Amyotrophic lateral sclerosis is a disease that causes progression in neurodegeneration in brain and spinal cord. In Amyotrophic lateral sclerosis, the muscle does not get adequate nourishment due to which it becomes atrophic. The disease occurs in the lateral region, an area in which spinal cord reflexes are found majorly. Therefore, the degeneration leads to hardening and scarring of muscles in that region. The progressive degeneration of neurons from brain to the spinal cord and spinal cord to the whole body can ultimately lead to their death. Amyotrophic lateral sclerosis is classified into two types, namely, sporadic and familial. Approximately 90% to 95% of the patients suffering from the disease in the U.S. are experience the sporadic.

NurOwn is a cell therapy platform that builds on the enormous research effort that has gone into developing mesenchymal stem cells (MSCs) as a treatment for human diseases.

The research also found that various companies have collaborated for the development of amyotrophic lateral sclerosis pipeline. In March 2013, Dainippon Sumitomo Pharma Co., Ltd. signed a research, development and commercial licensing agreement with Edison Pharmaceuticals, Inc. for EPI-743 and EPI-589 in Japan.

Some of the key players developing drugs for Amyotrophic lateral sclerosis include FlexPharma, Inc., Orion Corporation, Genervon Biopharmaceuticals, LLC, and others.

News Courtesy: P&S Market Research

Uveitis Exhibits Emerging Pipeline with 30+ Drug Candidates

Uveitis Therapeutics Pipeline

The study analyzed that the uveitis therapeutics pipeline comprises 33 drug candidates in different stages of development. Uveitis is a type of inflammatory disease that causes swelling and destroys eye tissues. Occurrence of this disease can result in slight reduction of vision or lead to complete vision loss. Uveitis occurs when the middle layer of the eyeball gets inflamed (red and swollen). This layer, known as the uvea, has many blood vessels that nourish the eye. Uveitis can damage vital eye tissue, even resulting in permanent vision loss.

pSivida Corp. is using durasert technology platform for the development of Medidur for the treatment of uveitis. This technology platform is used to provide sustained, localized delivery of drugs to the back of the eye. Durasert products are developed with a drug core surrounded with one or more polymer layers, the permeability of those layers and other aspects of the design of the product, controls the rate and duration of the drug release. However, changing the elements of the design, can help in altering both the rate and duration of release to meet different therapeutic needs. The later generation durasert products and product candidates are injected at the target site, while early generations were surgically implanted.

Some of the key players developing drugs for the treatment of uveitis include Aldeyra Therapeutics, Inc., EyeGate Pharmaceuticals, Inc., pSivida Corp. and others.

News Courtesy: P&S Market Research

Hemophilia Exhibits Emerging Pipeline with 53 Drug Candidates

Hemophilia Therapeutics Pipeline

The study analysed that the hemophilia pipeline comprises of 53 drug candidates in the pipeline in different stages of development for the treatment of hemophilia.

Most of the pharma and biotech companies are developing the therapeutics for hemophilia in collaboration with educational institutes. In September 2016, Roche in collaboration with Chugai Pharmaceutical Co. Ltd. initiated a Phase III trial to evaluate the safety, pharmacokinetics and efficacy of prophylactic subcutaneous emicizumab in patients (aged 12 years) suffering from hemophilia A without factor VIII inhibitors.

Many drug candidates received USFDA designations namely Orphan, Fast Track or Breakthrough designations in their clinical stages for the treatment of hemophilia. In August 2016, Orphan Drug Designation was granted to Phase III drug candidate of Chugai Pharmaceuticals, by Ministry of Health, Labour and Welfare, Japan.

Some of the key players developing drugs for the treatment of hemophilia include Sangamo BioSciences, Inc., Caisson Biotech, Inc., XL-protein GmbH, and others.

News Courtesy: P&S Market Research